Melanotan II vs PT-141

Melanotan II (MT-II) and PT-141 (bremelanotide) are synthetic melanocortin analogs derived from the same parent peptide, [Nle4, D-Phe7]-α-MSH. Their divergent receptor selectivity profiles create distinct clinical applications: MT-II produces tanning through MC1R activation, while PT-141 achieves sexual function through MC4R selectivity.

Melanocortin Receptor System

Humans express five melanocortin receptors (MC1R–MC5R) with distinct tissue distributions and functions:

Receptor	Location	Primary Function
MC1R	Skin melanocytes	Melanogenesis (tanning)
MC2R	Adrenal cortex	Cortisol synthesis (ACTH receptor)
MC3R	Hypothalamus	Energy homeostasis, feeding
MC4R	Hypothalamus, CNS	Sexual function, appetite, erectile response
MC5R	Exocrine glands	Sebaceous secretion

The selectivity ratio between MC1R and MC4R determines whether a melanocortin analog produces tanning or sexual effects.

Structural Basis for Selectivity

Melanotan II

MT-II is a cyclic heptapeptide analog of α-MSH:

• Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
• Cyclization: Lactam bridge between Asp and Lys side chains
• Modifications: Nle at position 4, D-Phe at position 7
• Receptor profile: Non-selective across MC1R–MC5R

The cyclization constrains the peptide into a conformation that simultaneously engages all melanocortin receptors with high affinity.

PT-141 (Bremelanotide)

PT-141 is a linear analog with reduced cyclization:

• Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ (open-chain form predominant)
• Modifications: Same as MT-II but without the lactam cyclization
• Receptor profile: MC4R >> MC3R > MC1R

The linear conformation selectively engages MC4R while reducing MC1R affinity, shifting the pharmacological profile from tanning to sexual function.

Receptor Binding Affinity

Receptor	Melanotan II EC₅₀	PT-141 EC₅₀	Selectivity Ratio (MC4R/MC1R)
MC1R	~0.5 nM	~10 nM	20× (PT-141 favors MC4R)
MC2R	>1 µM	>1 µM	N/A
MC3R	~1 nM	~2 nM	2×
MC4R	~0.5 nM	~0.5 nM	1× (equivalent)
MC5R	~2 nM	~20 nM	10× (PT-141 favors MC4R)

The critical difference is the 20-fold selectivity of PT-141 for MC4R over MC1R, compared to MT-II’s non-selective binding.

Tanning Effects

Melanotan II: Potent Tanning

• MC1R activation → tyrosinase upregulation → melanin synthesis
• Onset: 5–10 days of daily dosing
• Intensity: Deep brown pigmentation
• Duration: 2–4 weeks after discontinuation
• Distribution: Generalized, including normally sun-protected areas
• UV requirement: Can tan without UV exposure (though UV enhances effect)

PT-141: Minimal Tanning

• MC1R affinity: 20-fold lower than MT-II
• Clinical effect: 5–10% mild hyperpigmentation
• Distribution: Primarily face and hands
• Duration: Resolves within days of discontinuation
• UV requirement: No tanning effect without MC1R activation

Sexual Function Effects

PT-141: Sexual Function Focus

• FDA approval: Vyleesi (2019) for premenopausal hypoactive sexual desire disorder (HSDD)
• Mechanism: MC4R activation → hypothalamic dopamine release → sexual arousal
• Efficacy: 60% of women reported improved desire (vs 35% placebo)
• Onset: 30–60 minutes after SC injection
• Duration: 24–48 hours
• Application: Both female HSDD and male erectile dysfunction (investigational)

Melanotan II: Secondary Sexual Effects

• Mechanism: MC4R activation (shared with PT-141)
• Sexual effects: Present but non-selective (accompanied by tanning)
• Priapism risk: 1–3% in males (higher than PT-141)
• Application: Not used clinically for sexual function

Side Effect Comparison

Side Effect	Melanotan II	PT-141
Nausea	50–60%	40%
Flushing	30–40%	20%
Hyperpigmentation	80–90% (desired)	5–10% (unwanted)
Loss of appetite	30%	10%
Priapism (males)	1–3%	Rare
Blood pressure increase	10%	10–20%
Fatigue	20%	10%
Facial mole darkening	40%	Rare

PT-141 produces less nausea (40% vs 50–60%) and dramatically less hyperpigmentation, reflecting its MC4R selectivity.

Clinical Applications Summary

Application	Melanotan II	PT-141
Tanning	Primary use	Not indicated
Female HSDD	Investigational	FDA-approved (Vyleesi)
Male ED	Investigational	Investigational
Photoprotection	Investigational	Not indicated
Sexual dysfunction (general)	Off-label	Investigational
Melanoma risk	Concerning signal	Not assessed

Dosing Protocols

Melanotan II (Tanning Protocol)

Phase	Dose	Frequency	Duration
Loading	0.5–1 mg SC	Daily	10–14 days
Maintenance	0.5 mg SC	2–3× weekly	Ongoing
UV exposure	Optional	During loading	Enhances pigmentation

PT-141 (Sexual Function)

Parameter	Value
Dose	1.75 mg SC
Timing	45 min before sexual activity
Frequency	PRN (max 8 doses/month)
Route	Subcutaneous (autoinjector)
Storage	Room temperature

Safety Concerns

Melanotan II

• Melanoma risk: Potential for melanocyte stimulation in existing nevi
• Skin cancer: No long-term safety data; theoretical concern
• Cardiovascular: Flushing, blood pressure changes
• Injection site: Bruising, nodules

PT-141

• Nausea: Managed with antiemetics
• Hypertension: Transient blood pressure elevation
• Pregnancy: Contraindicated
• Combination risk: Avoid with other melanocortin agonists

Comparison Table

Feature	Melanotan II	PT-141
Receptor selectivity	Non-selective (MC1R–MC5R)	MC4R-selective
Primary indication	Tanning	Female HSDD
Tanning effect	Strong	Minimal
Sexual effect	Moderate	Strong
MC1R/MC4R ratio	~1:1	1:20
FDA status	Not approved	Approved (Vyleesi)
Nausea	50–60%	40%
Hyperpigmentation	80–90%	5–10%
Half-life	~1 hour	2.7 hours
Oral bioavailability	Low	Low

References

1. Hadley ME, et al. “Discovery and development of melanocortin agonists.” Peptides 2000;21:1587-1599.
2. Clayton AH, et al. “Bremelanotide for hypoactive sexual desire disorder in premenopausal women.” J Clin Psychiatry 2017;78:1156-1163.
3. Dorr RT, et al. “Tanning agent Melanotan II: pharmacology and clinical trials.” Cancer Chemother Pharmacol 1996;37:129-135.
4. Wikberg JES, et al. “Melanocortin receptors and their ligands.” Pharmacol Res 2000;42:285-294.
5. Goldstein I, et al. “Bremelanotide: new treatment for hypoactive sexual desire disorder.” Drugs 2019;79:501-512.